ÐÂÎÅÖÐÐÄ
News Center
ÖйúÉúÎïÖÆÒ©TQB2102Ñо¿¿¯µÇ¡¶JCO¡·£¬£¬£¬Ê׸ö¹úÑÐHER2Ë«¿¹ADCи¨ÖúÖÎÁÆÈéÏÙ°©È¡µÃÖ÷ҪͻÆÆ
Ðû²¼Ê±¼ä£º£º£º2025-11-26
11ÔÂ25ÈÕ£¬£¬£¬×¢ÉäÓÃTQB2102µ¥Ò©ÓÃÓÚHER2ÑôÐÔÈéÏÙ°©Ð¸¨ÖúÖÎÁƵĢòÆÚÁÙ´²Ñо¿Ð§¹û£¬£¬£¬»ñ¹ú¼ÊÖøÃûÆÚ¿¯¡¶ÁÙ´²Ö×ÁöѧÔÓÖ¾¡·£¨Journal of Clinical Oncology£¬£¬£¬IF 43.4) ÔÚÏß½ÒÏþ¡£¡£¡£TQB2102ÊÇÖйúÉúÎïÖÆÒ©£¨1177.HK£©ÆìÏÂÕý´óÌìÇç×ÔÖ÷Ñз¢µÄÒ»ÖÖ°ÐÏòHER2Á½¸ö·ÇÖصþ±íλECD2¼°ECD4µÄ¿¹ÌåżÁªÒ©ÎADC£©¡£¡£¡£¸ÃÏîÑо¿Óɸ´µ©´óѧÁ¥ÊôÖ×ÁöÒ½ÔºÉÛÖ¾Ãô½ÌÊÚÍŶÓÁìÏΣ¬£¬£¬ÎªÊ׸ö֤ʵ˫±íλHER2 ADC TQB2102ÔÚÈéÏÙ°©Ð¸¨ÖúÖÎÁƽ׶ξßÓÐÓÅÒìÁÆЧºÍÇå¾²ÐÔµÄÑо¿£¬£¬£¬¢óÆÚ×¢²áÁÙ´²Ñо¿ÕýÔÚ¿ªÕ¹ÖС£¡£¡£
.png/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20251126085912(1)__600x322.png "%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20251126085912(1)__600x322")
ÁÙ´²Äæ¾³£º£º£º½ü°ëÊýHER2ÑôÐÔÈéÏÙ°©»¼ÕßÐè¸üÓÅ·½°¸
HER2ÑôÐÔÈéÏÙ°©Õ¼ËùÓÐÈéÏÙ°©µÄ15%-20%£¬£¬£¬Õë¶Ô¢òÆں͢óÆÚ»¼Õßͨ³£ÍƼöи¨ÖúÖÎÁÆ£¬£¬£¬Ê×Ñ¡ÖÎÁÆ·½°¸Îª×ÏɼÀàºÍ²¬ÀàË«Ò©»¯ÁÆÁªºÏÇúÍ×Öéµ¥¿¹ºÍÅÁÍ×Öéµ¥¿¹Ë«°ÐÖÎÁÆ[1]¡£¡£¡£È»¶ø£¬£¬£¬ÈÔÓÐ45%-50%»¼ÕßÎÞ·¨µÖ´ï²¡ÀíÍêÈ«»º½â£¨pCR£©£¬£¬£¬±£´æδ֪×ãµÄÁÙ´²ÐèÇó[2-3]¡£¡£¡£
Ëæ×Å¿¹ÌåżÁªÒ©ÎADC£©ÔÚÍíÆÚHER2ÑôÐÔÈéÏÙ°©ÖÎÁÆÖÐÕ¹ÏÖ³öÏÔÖøÁÆЧ£¬£¬£¬ÁÙ´²×îÏÈ̽Ë÷½«ÕâÀàÒ©ÎïÍÆÏòÔçÆÚ»¼ÕßµÄи¨ÖúÖÎÁƳ¡¾°£¬£¬£¬ÒÔÆÚÍ»ÆÆÏÖÓÐÖÎÁÆÆ¿¾±¡£¡£¡£T-DM1ÊÇÊ׸ö»ñÅúÓÃÓÚHER2ÑôÐÔÈéÏÙ°©µÄADCÒ©Î£¬£¬µ«ÔÚи¨ÖúÖÎÁÆÖУ¬£¬£¬pCRÂʵÍÓÚ±ê×¼µÄ¶àÎ÷ËûÈü¡¢¡¢¿¨²¬¡¢¡¢ÇúÍ×Öéµ¥¿¹ºÍÅÁÍ×Öéµ¥¿¹·½°¸£¨44.4% vs 55.7%£©[3]¡£¡£¡£µ«Ëæ×ÅÏÂÒ»´ú¿¹HER2 ADCÒ©ÎïµÄÎÊÊÀ£¬£¬£¬Ð¸¨ÖúÖÎÁÆÁìÓòÓÀ´Êï¹â¡£¡£¡£Á½¿îµÚÈý´ú¿¹HER2 ADC»®·ÖÔÚ¢òÆں͢óËæ»ú±ÈÕÕÑо¿ÖÐÈ¡µÃÁ˺͹ŰåÖÎÁÆ·½°¸Ï൱»òÓÅÓڹŰåÖÎÁÆ·½°¸µÄÑо¿Ð§¹û£¬£¬£¬pCRÂÊ»®·ÖΪ63.2% vs 64.4%ºÍ67.3% vs 56.3%[4-5]¡£¡£¡£
.jpg/output%20(14)__600x400.jpg "output%20(14)__600x400")
ÔÚµÚÈý´ú¿¹ HER2 ADCµÄÑз¢À˳±ÖУ¬£¬£¬±¾ÍÁÁ¢ÒìÒ©ÎïÒ²Õ¹ÏÖ³öÆæÒìDZÁ¦£¬£¬£¬ÆäÖÐÕý´óÌìÇç×ÔÖ÷Ñз¢µÄTQB2102¼´ÊÇ´ú±íÐÔÒ©ÎïÖ®Ò»¡£¡£¡£TQB2102ÓÉ¿¹HER2Ë«ÌØÒìÐÔ¿¹Ìåͨ¹ý¿ÉÁѽâÅþÁ¬×ÓÅþÁ¬ÍØÆËÒ칹øIÒÖÖƼÁ×é³É£¬£¬£¬DARÖµ£¨Ò©ÎÌå±È£©Îª6¡£¡£¡£TQB2102ͬʱ°ÐÏòÁ½¸ö²»ÖصþµÄHER2±íλ£º£º£ºECD2£¨pertuzumabÁ¬ÏµÎ»µã£©ºÍECD4£¨trastuzumabÁ¬ÏµÎ»µã£©£¬£¬£¬´Ó¶øʵÏÖË«ÖØHER2ÐźÅ×è¶Ï£¬£¬£¬ÔöÇ¿ÖÎÁÆЧ¹û£¬£¬£¬ÓÐÍûÌáÉýHER2ÑôÐÔÈéÏÙ°©Ð¸¨ÖúÖÎÁÆЧ¹û¡£¡£¡£
Ñо¿Éè¼Æ£º£º£º¶àÐÐÁÐ̽Ë÷¼ÁÁ¿+ÖÜÆÚ¶ÔÁÆЧµÄÓ°Ïì
TQB2102-¢ò-01Ñо¿ÊǸ´µ©´óѧÁ¥ÊôÖ×ÁöÒ½ÔºÉÛÖ¾Ãô½ÌÊÚÍŶÓÁìÏοªÕ¹µÄÒ»Ï·Å±êÇ©¡¢¡¢Ëæ»ú¡¢¡¢¢òÆÚÁÙ´²ÊÔÑ飬£¬£¬Ö¼ÔÚ̽Ë÷TQB2102ÔÚHER2ÑôÐÔÈéÏÙ°©Ð¸¨ÖúÖÎÁÆÖеÄÓÐÓÃÐÔºÍÇå¾²ÐÔ¡£¡£¡£
Ñо¿ÄÉÈë¼ÈÍùδ¾ÏµÍ³ÐÔ¿¹Ö×ÁöÖÎÁƵĢò-¢óÆÚHER2ÑôÐÔÈéÏÙ°©ÊÜÊÔÕß¡£¡£¡£Æ¾Ö¤¼¤ËØÊÜÌ壨HR£©×´Ì¬¶ÔÊÜÊÔÕß¾ÙÐзֲ㣬£¬£¬²¢ÒÔ1:1±ÈÀýËæ»ú·ÖÅä½ÓÊÜTQB2102 6.0 mg/kgÖÎÁÆ6ÖÜÆÚ£¨ÐÐÁÐ1£©»ò8ÖÜÆÚ£¨ÐÐÁÐ2£©£¬£¬£¬»ò½ÓÊÜTQB2102 7.5 mg/kgÖÎÁÆ6ÖÜÆÚ£¨ÐÐÁÐ3£©»ò8ÖÜÆÚ£¨ÐÐÁÐ4£©¡£¡£¡£Ö÷ÒªÖÕµãÊÇËĸöÐÐÁеÄ×ܲ¡ÀíÍêÈ«»º½âÂÊ£¨tpCR£©£¬£¬£¬µ±tpCRÂʵÄ90%ÖÃÐÅÇø¼äÏÂÏÞ£¨CI£©Áè¼Ý40%ʱ£¬£¬£¬ÒÔΪÁÆЧÓÅÓÚÀúÊ·±ÈÕÕ¡£¡£¡£
ÁÁÑÛÊý¾Ý£º£º£º²¡ÀíÍêÈ«»º½âÂÊ´ï76.9%£¬£¬£¬ÓÅÓÚÀúÊ·±ÈÕÕ
ÔÚ2024Äê2ÔÂ5ÈÕÖÁ2024Äê9ÔÂ24ÈÕʱ´ú£¬£¬£¬4¸öÐÐÁй²ÄÉÈë104ÀýÊÜÊÔÕߣ¬£¬£¬Ã¿¸öÐÐÁÐ26Àý¡£¡£¡£¸÷ÐÐÁеÄHR״̬¡¢¡¢ÁÙ´²T·ÖÆÚ¡¢¡¢ÁÙ´²N·ÖÆÚ¡¢¡¢»ùÏßÖ×Áö·ÖÆÚ¼°HER2ÃâÒß×黯£¨IHC£©×´Ì¬Æ½ºâ¡£¡£¡£ÖÐλÄêËêΪ51Ë꣬£¬£¬Ô¼50%µÄ»¼ÕßΪHRÑôÐÔ£¬£¬£¬62.5%µÄ»¼ÕßΪ¢óÆÚ¡£¡£¡£
³ýÐÐÁÐ3ºÍÐÐÁÐ4¸÷1ÀýÊÜÊÔÕßδ½ÓÊÜÈéÏÙ°©ÊÖÊõÍ⣬£¬£¬¹²102ÀýÊÜÊÔÕßÍê³Éи¨ÖúÖÎÁƲ¢½ÓÊÜÈéÏÙ°©ÊÖÊõ¡£¡£¡£ÆäÖУ¬£¬£¬8ÖÜÆÚÐÐÁУ¨ÐÐÁÐ2ºÍÐÐÁÐ4£©ºÏ²¢ÆÊÎöµÄtpCRÂÊΪ73.1%£¬£¬£¬6mg/kg 8ÖÜÆÚÐÐÁУ¨ÐÐÁÐ2£©µÄtpCRÂʸߴï76.9%£¬£¬£¬4¸öÐÐÁÐËùÓÐÖª×ã“ÁÆЧÓÅÓÚÀúÊ·±ÈÕÕ”µÄÅжÏÌõ¼þ¡£¡£¡£
Çå¾²ÐÔ·½Ã棬£¬£¬×ÜÌå3¼¶ÖÎÁÆÏà¹Ø²»Á¼ÊÂÎñ±¬·¢ÂÊΪ27.9%£¬£¬£¬ÎÞÖÎÁÆÏà¹ØéæÃü±¨¸æ£¬£¬£¬ÁÙ´²Ëù¹Ø×¢µÄILD½ÏÇᣬ£¬£¬ÇÒ¾ÖÎÁƺó¿É»Ö¸´¡£¡£¡£
.png/11_25%E4%B8%AD(1)__600x320.png "11_25%E4%B8%AD(1)__600x320")
TQB2102-¢ò-01Ñо¿Ñо¿Ê×´Î֤ʵÁËË«±íλHER2 ADCÒ©ÎïTQB2102ÔÚHER2ÑôÐÔи¨ÖúÖÎÁƽ׶μòÖ±ÇÐÁÆЧºÍÓÅÒìÇå¾²ÐÔ£¬£¬£¬ÏÔʾTQB2102È¡µÃµÄtpCRÂÊÔÚÊýÖµÉϸßÓÚ¼ÈÍùHPË«°Ð+»¯ÁÆ£¬£¬£¬Ò²¸ßÓÚÆäËüµ¥±íλHER2 ADCÁÙ´²Ñо¿Öб¨¸æµÄpCRÊý¾Ý¡£¡£¡£»ùÓÚÒÔÉÏЧ¹û£¬£¬£¬TQB2102ÒÑ»ñ×¼¿ªÕ¹Ð¸¨ÖúÖÎÁÆHER2ÑôÐÔÈéÏÙ°©µÄ¢óÆÚ×¢²áÁÙ´²Ñо¿£¬£¬£¬ÓÐÍûÖØËÜHER2ÑôÐÔÈéÏÙ°©Ð¸¨ÖúµÄÖÎÁÆÃûÌᣡ£¡£
²Î¿¼ÎÄÏ×£º£º£º
[1] National Comprehensive Cancer Network: Breast Cancer (Version4.2024)
[2] Schneeweiss A, Chia S, Hickish T, et al: Pertuzumab plus trastuzumab
in combination with standard neoadjuvant anthracycline-containing and
anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278-2284, 2013
[3] Hurvitz SA, Martin M, Symmans WF, et al: Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19:115-126, 2018
[4] Li JJ, Wang ZH, Chen L, et al: Efficacy and safety of neoadjuvant SHR- A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial. Ann Oncol, 2025
[5] Nadia H, Shanu M, Lajos P, et al: DESTINY-Breast11 Trial Investigators. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial. Ann Oncol. 2025 Oct 18:S0923-7534(25)04968-3.
¡ø ÉÏÏ»¬¶¯Éó²é¸ü¶à
ÉùÃ÷£º£º£º
1. ±¾ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷£¬£¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬£¬£¬·Ç¹ã¸æÓÃ;¡£¡£¡£
2. ±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£¡£¡£
3. ±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬£¬£¬²»¿ÉÒÔÈκη½Ê½È¡´úרҵµÄÒ½ÁÆÖ¸µ¼£¬£¬£¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£¡£¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢£¬£¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£¡£¡£
Ç°Õ°ÐÔÉùÃ÷£º£º£º
±¾ÐÂΟåÖаüÀ¨Èô¸ÉÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬°üÀ¨Óйء¾TQB2102¡¿µÄÁÙ´²¿ª·¢ÍýÏë¡¢¡¢ÁÙ´²»ñÒæÓëÓÅÊƵÄÔ¤ÆÚ¡¢¡¢ÉÌÒµ»¯Õ¹Íû¡¢¡¢»¼ÕßÁÙ´²»ñÒæ¿ÉÄÜÐÔ£¬£¬£¬ÒÔ¼°Ç±ÔÚÉÌҵʱ»úµÈÉùÃ÷¡£¡£¡£“Ô¤ÆÚ”¡¢¡¢“ÏàÐÅ”¡¢¡¢“¼ÌÐø”¡¢¡¢“¿ÉÄÜ”¡¢¡¢“Ô¤¼Æ”¡¢¡¢“ÆÚÍû”¡¢¡¢“ÓÐÍû”¡¢¡¢“ÍýÏ딡¢¡¢“ÍýÏ딡¢¡¢“DZÔÚ”¡¢¡¢“Ô¤²â”¡¢¡¢“Ô¤¼Æ”¡¢¡¢“Ó¦¸Ã”¡¢¡¢“½«”¡¢¡¢“Ä┡¢¡¢“»á”ºÍÀàËƱí´ïÖ¼ÔÚʶ±ðÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬µ«²¢·ÇËùÓÐÇ°Õ°ÐÔ³ÂÊö¶¼°üÀ¨ÕâЩʶ±ð´Ê¡£¡£¡£ÕâЩǰհÐÔ³ÂÊöΪ¹«Ë¾»ùÓÚÄ¿½ñËùÕÆÎÕµÄÊý¾ÝºÍÐÅÏ¢Ëù×öµÄÔ¤²â»òÆÚÍû£¬£¬£¬¿ÉÄÜÒòÊܵ½Õþ²ß¡¢¡¢Ñз¢¡¢¡¢Êг¡¼°î¿ÏµµÈ²»È·¶¨ÒòËØ»ò·çÏÕµÄÓ°Ï죬£¬£¬¶øµ¼ÖÂÏÖʵЧ¹ûÓëÇ°Õ°ÐÔ³ÂÊöÓÐÖØ´ó²î±ð¡£¡£¡£ÇëÏÖÓлòDZÔÚµÄͶ×ÊÕßÉóÉ÷˼Á¿¿ÉÄܱ£´æµÄ·çÏÕ£¬£¬£¬²¢²»¿ÉÍêÈ«ÒÀÀµ±¾ÐÂΟåÖеÄÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬¸ÃµÈ³ÂÊö°üÀ¨ÐÅÏ¢½ö¼°ÓÚ±¾ÐÂΟåÐû²¼µ±ÈÕ¡£¡£¡£³ý·ÇÖ´·¨ÒªÇ󣬣¬£¬±¾¹«Ë¾ÎÞÒåÎñÒòÐÂÐÅÏ¢¡¢¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐζø¶Ô±¾ÐÂΟåÖÐÈκÎÇ°Õ°ÐÔ³ÂÊö¾ÙÐиüлòÐ޸ġ£¡£¡£